Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers [0.03%]
Hideaki Yamakawa,Kenji Kusano,Rie Kawabe et al.
Hideaki Yamakawa et al.
Background: Immune checkpoint inhibitors (ICIs) are effective in advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50 %; however, responses remain heterogeneous. We investigated the predictive value of n...
Luca Nicosia,Luciano Mariano,Carmen Mallardi et al.
Luca Nicosia et al.
Introduction: Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer increasingly detected through screening. While microcalcifications are the most common feature, a subset lacks them, posing diagnostic and mana...
Tissue and circulating proprotein convertase subtilisin/Kexin type 9 (PCSK9) as promising prognostic biomarkers for curative-intent colorectal liver metastases resection: A case-control study [0.03%]
Yun-Xin Lu,Wan-Ming Hu,Teng Fan et al.
Yun-Xin Lu et al.
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of cholesterol metabolism homeostasis. However, its significance in colorectal cancer liver metastasis (CRLM) remains undetermined. Here...
From pixels to prognosis: A QUADAS-2-Guided systematic review and meta-analysis of deep learning segmentation for DLBCL in PET and PET/CT [0.03%]
Sajad Keshavarz,Elham Saeedzadeh,Hossein Arabi et al.
Sajad Keshavarz et al.
This systematic review and meta-analysis evaluated the performance and methodological quality of deep learning models for automated segmentation of Diffuse Large B-Cell Lymphoma (DLBCL) on PET/CT imaging. A comprehensive literature search i...
SLFN5 as a dual-function oncogene and immune regulator: A pan-cancer multi-omics analysis linking prognosis, immune evasion, and therapeutic vulnerability [0.03%]
Fubiao Kang,Ziye Yang,Dong Li et al.
Fubiao Kang et al.
This study delineates the dual oncogenic and immunomodulatory functions of SLFN5 across a spectrum of human malignancies. By integrating comprehensive multi-omics analyses in breast, liver, and ovarian cancers, we demonstrate that elevated ...
Cancer treatment-related risk factors for stroke among patients with lung cancer: A systematic review and meta-analysis [0.03%]
肺癌患者相关脑卒中的致癌治疗因素的系统评价和 Meta 分析
Lotanna Ezeja,Sara Jaradat,Jingjing Qian
Lotanna Ezeja
Background: Lung cancer survivors can be at risk of stroke because of either malignancy or treatments. This systematic review with meta-analysis identified the risk of stroke associated with cancer treatments among patien...
Microvessel density as a prognostic factor in renal cell carcinoma: A systematic review and meta-analysis with individual patient data reconstructed from previous Kaplan‒Meier curves [0.03%]
微血管密度作为肾细胞癌预后因素的系统评价和个体患者数据汇总分析：基于之前Kaplan-Meier曲线重建的数据
Shulin Sun,Hongxian Zhang,Lulin Ma
Shulin Sun
Background: The prognostic value of microvessel density (MVD) in renal cell carcinoma (RCC) is controversial. This study aimed to clarify its significance by performing a meta-analysis with individual patient data (IPD) r...
Comparison of regorafenib and immunotherapy in colorectal cancer survival: A multicenter cohort study [0.03%]
regorafenib与免疫治疗在结直肠癌生存中的比较：一项多中心队列研究
Uzma Farzana,Raphael E Cuomo
Uzma Farzana
Background: Real-world comparative outcomes of regorafenib versus immune checkpoint inhibitors (ICI) after chemotherapy in colorectal cancer (CRC) are limited. ...
A GPC1-Targeting multifunctional nanoplatform combining paclitaxel-mediated chemotherapy and chlorin e6-assisted sonodynamic therapy for Pancreatic Ductal Adenocarcinoma (PDAC) treatment [0.03%]
一种GPC1靶向多功能纳米平台结合顺铂化疗和血红素e6辅助声动力疗法用于治疗胰腺导管腺癌(PDAC)
Bo Ren,Han-Mei Li,Ju-Ying Zhang et al.
Bo Ren et al.
Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most malignant tumours with limited treatment options and poor prognosis. This study designed a targeting nanoplatform, GCP@NBs, combining paclitaxel (PTX)-mediated chemotherapy...
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial [0.03%]
Durvalumab治疗意大利扩大用药项目中不可手术的局部晚期III期NSCLC患者的"中性粒细胞-淋巴细胞比值"(NLR)回顾分析：Neutrality试验结果
Chiara Mattioli,Emanuela Olmetto,Marco Banini et al.
Chiara Mattioli et al.
Background: Very little is known regarding the clinical value of inflammatory blood markers, such as NLR, Systemic Immune Inflammation (SII), derived NLR (dNLR) and Lung Immune Prognostic Index (LIPI) in stage III NSCLC p...